Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

Key clinical trials at EULAR 2019

Key clinical trials at EULAR 2019

FINCH 1

The phase III FINCH 1 trial compares filgotinib with placebo and the active comparator adalimumab in patients with active rheumatoid arthritis and an inadequate response to methotrexate.

Wednesday 12 June: 16:15–17:45
(Abstract LB0001)

SENSCIS

The SENSCIS investigators will present the results of their trial, published in The New England Journal of Medicine in May 2019, for EULAR 2019 attendees.

Wednesday 12 June: 16:15–17:45
(Abstract OP0017)

Tildrakizumab in PsA

This phase IIb placebo-controlled trial aims to investigate the safety and efficacy profiles of the anti-interleukin-23P19 monoclonal antibody tildrakizumab in patients with active psoriatic arthritis.

Wednesday 12 June: 16:15–17:45
(Abstract LB0002)

Fenebrutinib in RA

This study is a phase II trial of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) compared with placebo and adalimumab in patients with rheumatoid arthritis and an inadequate response to prior methotrexate or tumor necrosis factor inhibitor therapy.

Wednesday 12 June: 16:15–17:45
(Abstract OP0025)

Prednisone tapering in RA

This phase IIIb/IV trial compared glucocorticoid tapering versus continuation among rheumatoid arthritis patients receiving tocilizumab treatment.

Wednesday 12 June: 16:15–17:45
(Abstract OP0030)

IM101-603

IM101-603 is a phase III placebo-controlled trial investigating the efficacy and safety of subcutaneous abatacept in adults with active primary Sjögren's syndrome.

Wednesday 12 June: 16:15–17:45
(Abstract OP0039)

ASAP-III

This phase III trial also aims to compare the efficacy and safety profile of subcutaneous abatacept with that of placebo in adult patients with primary Sjögren's syndrome.

Wednesday 12 June: 16:15–17:45
(Abstract OP0045)

FINCH 3

The FINCH 3 investigators will present the results of their phase III trial of filgotinib, given alone or in combination with methotrexate, in patients with moderate-to-severe rheumatoid arthritis and no prior methotrexate exposure.

Saturday 15 June: 08:00–09:00
(Abstract LB003)

ORAL Shift

ORAL Shift is a noninferiority phase III/IV study investigating whether methotrexate can be withdrawn in patients with rheumatoid arthritis receiving treatment with tofacitinib.

Saturday 15 June: 08:00–09:00
(Abstract LB0004)

SPIRIT-H2H

The SPIRIT-H2H results will provide data on the comparative efficacy and safety profiles of ixekizumab and adalimumab in biologic-naïve patients with psoriatic arthritis.

Saturday 15 June: 08:00–09:00
(Abstract LB005)

HLA-DRB1 alleles and treatment response in RA

This phase IV trial examined whether HLA-DRB1 alleles containing the shared epitope are associated with the efficacy of abatacept or adalimumab in biologic-naïve patients with early rheumatoid arthritis who were seropositive for anti-cyclic citrullinated protein 2 antibodies.

Saturday 15 June: 08:00–09:00
(Abstract LB0008)

APTITUDE

The APTITUDE trial is a phase II study of tocilizumab in patients with juvenile idiopathic arthritis-associated uveitis refractory to tumor necrosis factor inhibitors.

Saturday 15 June: 08:00–09:00
(Abstract LB0011)